Dr. Valliant is Founder and Chief Executive Officer of Fusion Pharmaceuticals. Dr. Valliant has been instrumental in securing both investment and scientific and medical collaborations with the industrial and academic partners of Fusion.

Prior to Fusion, Dr. Valliant founded the Centre for Probe Development and Commercialization (CPDC), a radiopharmaceutical research and development centre of excellence established in 2008 through funding from the Federal and Provincial governments, industry and academic partners. The CPDC is focused on discovering, developing and distributing the next generation of molecular imaging probes. The CPDC also plays an important role in Canada’s health care system, manufacturing and delivering a reliable, daily supply of imaging probes to hospitals and clinics nationally and internationally.
Dr. Valliant is also a Professor in the Department of Chemistry and Chemical Biology at McMaster University.

In 2009, Dr. Valliant was selected as one of Canada’s Top 40, Under 40, a distinction that recognizes his work at CPDC and McMaster University to advance molecular imaging probe technologies, improve patient care and spur economic growth through the commercialization of Canadian technologies. In 2015, he received the Brockhouse Canada Prize for Interdisciplinary Research in Science and Engineering from NSERC, recognizing his contribution to a team of researchers from physics, chemistry and nuclear medicine, who developed a breakthrough technology that uses hospital-based cyclotrons to produce critical medical isotopes.

Dr. Valliant completed his PhD at McMaster University, and followed with a post-doctoral fellowship under the joint supervision of professors Alun G. Jones (Harvard) and Alan Davison (MIT).

Dr. Burak has more than 20 years of pharmaceutical research and development experience in both biotechnology and large pharmaceutical companies. Before joining Fusion, he was Vice President of Development at Theracos Inc., where he was responsible for all research, clinical development and manufacturing activities for a company developing drugs to treat Type 2 diabetes. Previous positions include Vice President of Preclinical and Early Clinical Development at Rib-X Pharmaceuticals, Inc., a venture-funded antibiotic company, and Director of Drug Metabolism and Pharmacokinetics at Guilford Pharmaceuticals, Inc.

Dr. Burak’s experience has focused on integrating discovery and development processes to accelerate the identification and development of new therapeutic agents. He has submitted 14 Investigational New Drug Applications (INDs) and has developed two approved products across multiple therapeutic areas including oncology, cardiovascular, antibiotics, diseases of the central and peripheral nervous system, anesthesia/sedation, diabetes, and wound healing.

Dr. Burak holds a PhD in Analytical Chemistry from Temple University and a BSc in Chemistry from Drexel University.

Mr. Crowley brings over 20 years of global finance and operational experience in the life sciences industry to Fusion. He most recently served as Executive Vice President and Chief Financial Officer of Merus, Inc., a publicly traded oncology company, where he led the execution of financial strategy and operations as well as investor relations activities. Prior to Merus, Mr. Crowley served as the Corporate Senior Vice President, Corporate Controller and Chief Accounting Officer of Charles River Laboratories, Inc. where he implemented a finance transformation initiative to restructure the finance operating model in support of an aggressive acquisition strategy. Previously, Mr. Crowley held senior corporate finance positions at Ironwood Pharmaceuticals, Inc., Vertex Pharmaceuticals, Inc., and Sunovion Pharmaceuticals, Inc., where he supported several commercial launches, financings, and business development transactions in rapidly growing companies. Mr. Crowley is a Certified Public Accountant and graduated Summa Cum Laude from Babson College with BS degrees in both Economics and Accountancy.

Dr. Leamon was most recently executive director, radioligand drug discovery at Novartis. Prior to Novartis, he was vice president, discovery research at Advanced Accelerator Applications, a subsidiary acquired by Novartis in 2018. Before that, he held several positions within Endocyte, including vice president of research and most recently, president. At Endocyte he contributed to the research and development of the company's PSMA-targeted radioligand therapy program for metastatic castration-resistant prostate cancer prior to the acquisition by Novartis. Prior to Endocyte, Dr. Leamon held various research and development roles at Ionis Pharmaceuticals and GlaxoSmithKline. Dr. Leamon obtained a bachelor of science degree in chemistry from Baldwin Wallace University, and a doctor of philosophy degree in chemistry, with a concentration in biochemistry, from Purdue University.

Dr. Ferreira brings a unique background of business strategy and radiopharmaceutical science to the Fusion Pharmaceuticals team. Prior to joining Fusion Pharmaceuticals, Dr. Ferreira was an Associate Partner at the global consulting firm McKinsey & Company where she was a leader in the Pharmaceutical Practice and the Healthcare Investing Service Line. During her time at McKinsey, Dr. Ferreira advised pharmaceutical and biotechnology companies on a range of topics include corporate strategy, innovation, portfolio optimization, acquisitions and in-licensing, and new product launch. She also advised private equity on investment opportunities in the healthcare and pharmaceutical space.

Previously, she was a Senior Development Officer in the R&D group of Nordion (division acquired by BWXT), a global leader in medical isotopes and radiopharmaceuticals. At Nordion, Dr. Ferreira lead research in diagnostic and therapeutic radiopharmaceuticals both internally and through numerous external collaborations with industry and academia. Active in the nuclear medicine community, Dr. Ferreira has held numerous elected positions with the Society of Nuclear Medicine and Molecular Imaging including President of the Radiopharmaceuticals Science Council and member of the House of Delegates.

Dr. Ferreira holds a PhD in radiochemistry and an MBA in strategic management for the University of British Columbia.

Ms. Stahl brings to Fusion a breadth of legal and operational experience within the biopharmaceutical industry. Prior to joining Fusion, Ms. Stahl held executive leadership roles at Tetraphase Pharmaceuticals, including chief business officer and general counsel. Before joining Tetraphase, Ms. Stahl was the senior vice president, general counsel of Idenix Pharmaceuticals. Ms. Stahl began her career with the law firm Wilmer Cutler Pickering Hale and Dorr LLP. Ms. Stahl holds a bachelor of arts from Providence College and a juris doctorate from Yale Law School.

Dr. Paulus has over 30 years of experience in the pharmaceutical industry, including over 20 years specializing in Regulatory Affairs. Prior to joining Fusion, Dr. Paulus was Senior Vice President, Regulatory Affairs at Abeona Therapeutics. Prior to joining Abeona, he served as Vice President and Global Head of Regulatory Affairs at the clinical-stage immunotherapy company Hookipa Pharma. Previously, Dr. Paulus was Global Head of Regulatory Affairs for Advanced Accelerator Applications, a Novartis Company, where he secured orphan designations and product approvals for Gallium Ga68 dotatate and Lutetium Lu177 dotatate. Earlier in his career, Dr. Paulus served as Director of Regulatory Affairs for Pediatric Vaccines at GlaxoSmithKline and Senior Director of Regulatory Affairs for Biosimilar drug development at Dr. Reddy’s. He also held roles of increasing responsibility at Organon, Elusys Therapeutics, and the Population Council. Dr. Paulus began his career as a laboratory technician at the Salk Institute manufacturing vaccines for the US Army and then managed a cell culture laboratory at Centocor and viral vaccine production at what is now Sanofi Pasteur. He was also Manager of Regulatory Affairs for MCM (Merck-Connaught-Merieux), developing novel combination pediatric vaccines. Dr. Paulus has BSc degrees in Biology and Biochemistry, an MSc in biology (parasitology) and a Ph.D. in public health.

Dr. Hoffman has more than 15 years' experience in the biotechnology industry, most recently acting as chief business officer at Vicarius Pharma, where he led successful business development efforts to in-license European commercialization rights for oncology and other products. Prior to Vicarius, he was chief business officer of Genocea Biosciences where he led business development, alliance management and commercial operations. Prior to Genocea, he was vice president of corporate and business development and executive director of investor relations and corporate communications at Idenix Pharmaceuticals until the acquisition by Merck & Co. Dr. Hoffman was previously director of corporate and business development and director of investor relations at Biogen Idec. He also previously worked for more than five years on Wall Street as a biotechnology equity analyst at JPMorgan Securities and a biotechnology research associate at Bear Stearns International. Dr. Hoffman was a post-doctoral research associate in the Department of Immunobiology at King's College in London. He holds a Ph.D. in molecular, cellular and developmental biology with a focus on T cell immunology from Yale University, and a B.S. in biology from Trinity University.

Mr. Rawat was most recently vice president and global disease lead for the $3 billion CML franchise (including asciminib/ABL001 and TASIGNA) at Novartis Oncology where he helped bring forward for approval and potential blockbuster success the FDA-designated priority review STAMP inhibitor asciminib. Prior to this role, he was the U.S. marketing director for COSENTYX, where he led multiple commercial and strategic efforts for Novartis' top product with more than $4 billion in sales; and executive director, early-stage pipeline, for NASH, cardiovascular, renal and metabolism, also at Novartis. Before joining Novartis, Mr. Rawat was asset team lead, senior director, immunology and neuroscience at AbbVie Pharmaceuticals. Prior to that, he was with McKinsey and Company, where he was a leader in the biopharmaceutical practice and led client teams on business development, research and development, product commercialization and strategy projects. Earlier in his career, Mr. Rawat held several positions of increasing responsibility within Novartis Pharmaceuticals, across marketing and sales, drug development and portfolio planning. Mr. Rawat holds an M.B.A. from Harvard Business School, an M.S. in chemical engineering from Massachusetts Institute of Technology (MIT), a certificate in finance from Sloane School of Management at MIT, and M. Tech. and B. Tech. degrees in chemical engineering from Indian Institute of Technology (IIT).

Dr. Bobilev joined Fusion from Checkmate Pharma, where he was vice president, head of clinical development until the company’s acquisition by Regeneron earlier in 2022. At Checkmate, he was responsible for clinical development strategy for vidutolimod. Prior to Checkmate, Dr. Bobilev was vice president, head of clinical development at Vedanta Biosciences. He previously held clinical development leadership roles with Tesaro and Sanofi. Dr. Bobilev spent more than 10 years as a practicing medical and radiation oncologist.